“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader
Executive Summary
Though AstraZeneca is in several ways playing catch up in the oncology space, a strategy built around speed, differentiation and carving out areas of leadership has the firm poised for transformation. Execs are particularly confident the company will become a dominant force as combinations become a larger part of cancer care, pulling from its immunotherapeutic and small molecule pipelines.
You may also be interested in...
AstraZeneca's Cediranib Filing Withdrawal: CHMP Had Two Major Issues
European filing for ovarian cancer candidate cediranib was undone by differences in opinion between AstraZeneca and EMA's CHMP advisory committee in two key areas – the clinical benefit, and compliance with GCP.
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline
The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.